JP2018512394A - 多発性骨髄腫のロネパルスタット併用療法 - Google Patents

多発性骨髄腫のロネパルスタット併用療法 Download PDF

Info

Publication number
JP2018512394A
JP2018512394A JP2017546847A JP2017546847A JP2018512394A JP 2018512394 A JP2018512394 A JP 2018512394A JP 2017546847 A JP2017546847 A JP 2017546847A JP 2017546847 A JP2017546847 A JP 2017546847A JP 2018512394 A JP2018512394 A JP 2018512394A
Authority
JP
Japan
Prior art keywords
tat
use according
melphalan
administered
day
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2017546847A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018512394A5 (enExample
Inventor
ラルフ・ディ・サンダーソン
ビシュヌ・プラカシュ・シー・ラマニ
アレッサンドロ・ノセダ
パオラ・バルビエリ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Leadiant Biosciences SA
Original Assignee
Leadiant Biosciences SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Leadiant Biosciences SA filed Critical Leadiant Biosciences SA
Publication of JP2018512394A publication Critical patent/JP2018512394A/ja
Publication of JP2018512394A5 publication Critical patent/JP2018512394A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
    • A61K31/727—Heparin; Heparan
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/69—Boron compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/05—Dipeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/07—Tetrapeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Dermatology (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2017546847A 2015-03-06 2016-03-03 多発性骨髄腫のロネパルスタット併用療法 Pending JP2018512394A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201562129221P 2015-03-06 2015-03-06
US62/129,221 2015-03-06
US201562153899P 2015-04-28 2015-04-28
US62/153,899 2015-04-28
PCT/IB2016/051196 WO2016142814A1 (en) 2015-03-06 2016-03-03 Roneparstat combined therapy of multiple myeloma

Publications (2)

Publication Number Publication Date
JP2018512394A true JP2018512394A (ja) 2018-05-17
JP2018512394A5 JP2018512394A5 (enExample) 2018-12-27

Family

ID=55521766

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2017546847A Pending JP2018512394A (ja) 2015-03-06 2016-03-03 多発性骨髄腫のロネパルスタット併用療法

Country Status (16)

Country Link
US (1) US10576101B2 (enExample)
EP (2) EP3453389A1 (enExample)
JP (1) JP2018512394A (enExample)
KR (1) KR20170138405A (enExample)
CN (1) CN107645954A (enExample)
AU (1) AU2016230859A1 (enExample)
BR (1) BR112017018869A2 (enExample)
CA (1) CA2978040A1 (enExample)
DK (1) DK3265075T3 (enExample)
ES (1) ES2715556T3 (enExample)
HK (1) HK1245107A1 (enExample)
HU (1) HUE042681T2 (enExample)
MX (1) MX2017011093A (enExample)
PL (1) PL3265075T3 (enExample)
PT (1) PT3265075T (enExample)
WO (1) WO2016142814A1 (enExample)

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8727157D0 (en) * 1987-11-19 1987-12-23 Wellcome Found Pharmaceutical formulations
IT1316986B1 (it) 2000-01-25 2003-05-26 Sigma Tau Ind Farmaceuti Derivati glicosamminoglicani parzialmente desolfatati nonanticoagulanti ad attivita' antiangiogenica.
US20050137167A1 (en) 2001-09-12 2005-06-23 Benito Casu Derivatives of partially desulphated glycosaminoglycans as heparanase inhibitors, endowed with antiangiogenic activity and devoid of anticoagulating effect
US7781416B2 (en) 2000-01-25 2010-08-24 Sigma-Tau Research Switzerland S.A. Derivatives of partially desulphated glycosaminoglycans as heparanase inhibitors, endowed with antiangiogenic activity and devoid of anticoagulating effect
WO2009151569A2 (en) * 2008-06-09 2009-12-17 Combinatorx, Incorporated Beta adrenergic receptor agonists for the treatment of b-cell proliferative disorders

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
CLIN CANCER RES, vol. 17, no. 6, JPN6019028049, 2011, pages 1382 - 1393, ISSN: 0004224402 *
EXPERT OPINION ON INVESTIGATIONAL DRUGS, vol. 16, no. 9, JPN6019028056, 2007, pages 1467 - 1488, ISSN: 0004224404 *
PHARMACEUTICALS, vol. 8, JPN6019028051, 2015, pages 1 - 20, ISSN: 0004224403 *

Also Published As

Publication number Publication date
PT3265075T (pt) 2019-03-25
EP3265075A1 (en) 2018-01-10
WO2016142814A1 (en) 2016-09-15
BR112017018869A2 (pt) 2018-04-17
US10576101B2 (en) 2020-03-03
EP3453389A1 (en) 2019-03-13
AU2016230859A1 (en) 2017-08-17
MX2017011093A (es) 2018-02-19
PL3265075T3 (pl) 2020-10-05
CN107645954A (zh) 2018-01-30
CA2978040A1 (en) 2016-09-15
HUE042681T2 (hu) 2019-07-29
ES2715556T3 (es) 2019-06-04
DK3265075T3 (en) 2019-04-08
KR20170138405A (ko) 2017-12-15
US20180050061A1 (en) 2018-02-22
HK1245107A1 (zh) 2018-08-24
EP3265075B1 (en) 2018-12-12

Similar Documents

Publication Publication Date Title
US11826317B2 (en) Combination therapy with notch and PD-1 or PD-L1 inhibitors
JP5340935B2 (ja) 抗ｃｓ１抗体に基づく組合せ療法を用いて多発性骨髄腫を処置する方法
DK2582683T3 (en) TREATMENT OF Gout and Hyperuricemia
JP2016532667A (ja) ヒストンデアセチラーゼ阻害薬及び免疫調節薬の組み合わせ
JP2021532126A (ja) アルツハイマー病の治療及び予防方法
US12390434B2 (en) Compositions and methods for reducing immune intolerance and treating autoimmune disorders
CN113574068B (zh) 诱导抗癌免疫应答的方法
CN113260363A (zh) 格拉普兰特(grapiprant)单位剂型
CN118946371A (zh) 靶向psma的放射性药物和检查点抑制剂的组合疗法
JP2022533697A (ja) Ｇａｐｄｈを阻害する方法及び組成物
WO2022173334A2 (en) Methods, compositions and compounds for treating age-related diseases and conditions
US20230041515A1 (en) Dosing of a bruton's tyrosine kinase inhibitor
US10576101B2 (en) Roneparstat combined therapy of multiple myeloma
JP7504106B2 (ja) がんの処置のための組合せ物
JP2014009218A (ja) 細胞融合阻害剤及びその用途
CN104053441B (zh) 用于预防或治疗高脂血症的药物组合物
WO2022016231A1 (en) Methods of treatment
CN117440828A (zh) 使用组合疗法治疗多发性骨髓瘤的方法
NZ788615A9 (en) Dosing of a bruton's tyrosine kinase inhibitor
HK40056021A (en) Methods of inducing an anti-cancer immune response
EA039396B1 (ru) Лечение рака молочной железы с тройным негативным фенотипом ингибиторами tor-киназы

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20181114

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20181114

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20190723

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20190724

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20200303